Understanding Uveal Melanoma: Diagnosis, Spread, and Modern Treatment Options

Uveal melanoma is a rare form of cancer that develops in the eye’s uvea, which includes the iris, ciliary body, and choroid. While it is the most common primary intraocular malignancy in adults, it frequently metastasizes to the liver. According to the American Society of Clinical Oncology, early detection through regular comprehensive eye exams remains the most effective strategy for improving patient outcomes.

How Uveal Melanoma Develops and Spreads

The uvea is the middle layer of the eye, rich in blood vessels and melanocytes—the cells responsible for producing pigment. When these cells undergo malignant transformation, they form a tumor. Because the uvea is highly vascular, it provides a direct pathway for cancer cells to enter the bloodstream.

The American Cancer Society notes that in about 50% of cases, uveal melanoma spreads (metastasizes) to other parts of the body, with the liver being the most common site of distant recurrence. This pattern of spread occurs even after the primary tumor in the eye has been successfully treated with surgery, radiation, or plaque brachytherapy.

Current Treatment Modalities for Metastatic Disease

When uveal melanoma spreads to the liver, treatment shifts from local control of the eye tumor to systemic or liver-directed therapies. The management of metastatic uveal melanoma has historically been challenging due to limited response rates to traditional chemotherapy.

* Liver-Directed Therapies: For patients with tumors confined primarily to the liver, specialists may use procedures like hepatic artery infusion or selective internal radiation therapy (SIRT) to deliver treatment directly to the liver while sparing healthy tissue.
* Systemic Therapies: Immunotherapy and targeted therapies are the current focus of clinical research. In 2022, the U.S. Food and Drug Administration (FDA) approved tebentafusp-tebn, the first systemic treatment specifically for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. This drug works by directing T-cells to identify and destroy cancer cells.
* Clinical Trials: Many patients seek enrollment in clinical trials to access experimental agents, such as newer checkpoint inhibitors or combination therapies, which are currently being investigated to improve survival rates.

Key Takeaways for Patients and Families

* Monitor Symptoms: Changes in vision, such as blurred vision, flashes of light, or the appearance of “floaters,” warrant an immediate examination by an ophthalmologist.
* Genetic Testing: Following a diagnosis, doctors often perform genetic testing on the tumor tissue. Certain genetic mutations, such as those in the BAP1 gene, can help clinicians predict the risk of metastasis.
* Multidisciplinary Care: Managing metastatic uveal melanoma requires a team approach involving ophthalmologists, medical oncologists, and interventional radiologists.

Frequently Asked Questions

Is uveal melanoma the same as skin melanoma?
No. While both involve melanocytes, uveal melanoma is biologically distinct from cutaneous (skin) melanoma. It does not typically respond to the same standard immunotherapies used for skin cancer.

Can uveal melanoma be prevented?
There are no definitive lifestyle changes to prevent uveal melanoma. However, protecting the eyes from ultraviolet (UV) radiation by wearing sunglasses is a general recommendation for ocular health.

What is the prognosis for metastatic uveal melanoma?
Prognosis varies significantly based on the extent of the disease and the specific genetic profile of the tumor. Advances in targeted therapies like tebentafusp have provided new options for patients who previously had few treatment alternatives, though long-term data on these newer treatments is still being gathered through ongoing clinical observation.